Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 9:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: COVID-19 Testing Behaviors
Interventions: Text message-based education intervention, Historical Control; Behavioral · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 89 Years
Enrollment: 384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Brownsville, Texas • Houston, Texas • Tyler, Texas

Conditions: COPD
Interventions: Formoterol Fumarate; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 44
States / cities: Jasper, Alabama • Phoenix, Arizona • Tuscon, Arizona + 40 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Rimonabant, Placebo (for Rimonabant), Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Healthy
Interventions: NRX-1074, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Uncontrolled Hypertension
Interventions: CIN-107, Placebo; Drug
Lead sponsor: CinCor Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 63
States / cities: Saraland, Alabama • Tucson, Arizona • Encinitas, California + 55 more

Conditions: Diabetic Nephropathy
Interventions: Pyridoxamine Dihydrochloride, Placebo; Drug
Lead sponsor: NephroGenex, Inc.; Industry
Eligibility: 25 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 35
States / cities: Phoenix, Arizona • Scottsdale, Arizona • North Little Rock, Arkansas + 31 more

Conditions: Non-segmental Vitiligo
Interventions: GIA632, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • San Diego, California + 21 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK716155, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Intensive Care Unit ICU, Intubation, Critical Illness, Mechanical Ventilation, Pain Measurement, Pain, Procedural, Oxidative Stress, Hypoxia, Biomarkers / Blood, Adult, Uric Acid, Sepsis, COVID, Influenza, Pneumonia
Interventions: endotracheal tube suctioning; Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Placebo, Sotatercept, SOC; Drug · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 12
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 7 more

Conditions: Perimenopause
Interventions: Revive Product Form - Placebo Control, Revive Product Form - Active; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 37 Years to 55 Years · Female only
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 48
States / cities: Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more

Conditions: Painful Diabetic Neuropathy
Interventions: Nerve Decompression; Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders, Nutritional and Metabolic Diseases, Body Weight
Interventions: PF-08653945, PF-08653944, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 53
States / cities: Sun City West, Arizona • Canoga Park, California • Fountain Valley, California + 45 more

Conditions: Infant/ Neonate Lumbar Puncture
Interventions: Ultrasound assisted lumbar puncture; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Up to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Breast Cancer
Interventions: celecoxib 400 mg bid; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 7
States / cities: Birmingham, Alabama • Palm Springs, California • Maywood, Illinois + 4 more

Conditions: Colorectal Cancer Screening
Interventions: 3 sample g-SENSA, 2 sample InSure, 1 sample OC-Micron; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 50 Years to 74 Years
Enrollment: 2,260 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Amputation
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 21 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Generalized Myasthenia Gravis
Interventions: Rozanolixizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 23 more

Conditions: Healthy Subjects
Interventions: AV650; Drug
Lead sponsor: Avigen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Interventions: LNA043, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Enteric Hyperoxaluria
Interventions: ALLN-177, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Obese
Interventions: Standard PEEP (8 cmH₂O); Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes

Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers

A Study of CIN-107 in Patients With Uncontrolled Hypertension

Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.

The Effects of Endotracheal Suctioning on Pain and Serum Markers

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

Radicle Revive™ CSP: A Trial Evaluating Plant-Based Health and Wellness Products on Perimenopausal Women's Self-Reported Health Issues and Outcomes

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

Study on the Role of Decompression of Lower Extremity Nerves for the Treatment of Patients With Symptomatic Diabetic Neuropathy With Chronic Nerve Compression

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

Bedside Ultrasound Assisted Pediatric Lumbar Puncture

A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy

Systems of Support (SOS) to Increase Colon Cancer Screening and Follow-up Supplement

Comparison of Prosthetic Knee Performance During Sitting and Standing

A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650

First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement

Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria

Mechanical Ventilation in Obese Surgical Patients